Mohamed I Elsaid (Mohamed Elsaid)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 22

Top Venues

PloS one

Alimentary pharmacology & therapeutics

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of clinical and translational hepatology

Rutgers Robert Wood Johnson Medical School

Rutgers University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rutgers Robert Wood Johnson Medical School Oct 01 2017

United States

Research Specialist :: Gastroenterology and Hepatology

Education History

Rutgers University Jan 20 2015

United States

PHD :: Epidemiology

Publications

Mohamed I Elsaid, John F P Bridges, Khalid Mumtaz, Na Li, Lindsay Sobotka, Vinod K Rustgi, Electra D Paskett
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PloS one 19 (3) (2024)
J C Chen, Mohamed I Elsaid, Demond Handley, Jesse J Plascak, Barbara L Andersen, William E Carson, Timothy M Pawlik, Naleef Fareed, Samilia Obeng-Gyasi
Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, John F P Bridges, Khalid Mumtaz, Na Li, Lindsay Sobotka, Vinod K Rustgi, Electra D Paskett
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PloS one 19 (3) (2024)
Mohamed I Elsaid, John F P Bridges, Khalid Mumtaz, Na Li, Lindsay Sobotka, Vinod K Rustgi, Electra D Paskett
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PloS one 19 (3) (2024)
J C Chen, Mohamed I Elsaid, Demond Handley, Jesse J Plascak, Barbara L Andersen, William E Carson, Timothy M Pawlik, Naleef Fareed, Samilia Obeng-Gyasi
Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Mohamed I Elsaid, John F P Bridges, Khalid Mumtaz, Na Li, Lindsay Sobotka, Vinod K Rustgi, Electra D Paskett
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PloS one 19 (3) (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics (2024)
J C Chen, Mohamed I Elsaid, Demond Handley, Jesse J Plascak, Barbara L Andersen, William E Carson, Timothy M Pawlik, Naleef Fareed, Samilia Obeng-Gyasi
Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett, Chathur Acharya, Rajender K Reddy, Chien Wei Chiang, Khalid Mumtaz
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Alimentary pharmacology & therapeutics 59 (9) (2024)
Mohamed I Elsaid, Xiaochen Zhang, Anne L R Schuster, Jesse J Plascak, Cecilia DeGraffinreid, Electra D Paskett
The impact of socioeconomic status on changes in cancer prevention behavior during the COVID-19 pandemic. PloS one 18 (6) (2023)
Mohamed I Elsaid, Xiaochen Zhang, Anne L R Schuster, Jesse J Plascak, Cecilia DeGraffinreid, Electra D Paskett
The impact of socioeconomic status on changes in cancer prevention behavior during the COVID-19 pandemic. PloS one 18 (6) (2023)
Xiaochen Zhang, Mohamed I Elsaid, Cecilia DeGraffinreid, Victoria L Champion, Electra D Paskett, null null
Impact of the COVID-19 Pandemic on Cancer Screening Delays. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mohamed I Elsaid, Xiaochen Zhang, Anne L R Schuster, Jesse J Plascak, Cecilia DeGraffinreid, Electra D Paskett
The impact of socioeconomic status on changes in cancer prevention behavior during the COVID-19 pandemic. PloS one 18 (6) (2023)
Ankoor H Patel, Dhiraj Peddu, Sahil Amin, Mohamed I Elsaid, Carlos D Minacapelli, Toni-Marie Chandler, Carolyn Catalano, Vinod K Rustgi
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. Journal of clinical and translational hepatology 11 (2) (2022)
Norah L Crossnohere, Mohamed I Elsaid, Jonathan Paskett, Seuli Bose Brill, John F P Bridges
Guidelines for Artificial Intelligence in Medicine: Literature Review and Content Analysis of Frameworks. Journal of medical Internet research 24 (8) (2022)
Ankoor H Patel, Dhiraj Peddu, Sahil Amin, Mohamed I Elsaid, Carlos D Minacapelli, Toni-Marie Chandler, Carolyn Catalano, Vinod K Rustgi
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. Journal of clinical and translational hepatology 11 (2) (2022)
Vinod K Rustgi, Steven B Duff, Mohamed I Elsaid
Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. Journal of medical economics 25 (1) (2022)
Mohamed I Elsaid, You Li, Tina John, Navaneeth Narayanan, Carolyn Catalano, Vinod K Rustgi
Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States. Hepatology (Baltimore, Md.) 72 (2) (2020)
Vinod K Rustgi, You Li, Tina John, Carolyn Catalano, Mohamed I Elsaid
Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real-World Claims Analysis. Hepatology communications 4 (10) (2020)

Mohamed I Elsaid.css-eqlu8i{font-size:small;padding-left:4px;} (Mohamed Elsaid)

Publication Activity (10 Years)

Top Topics

Top Venues

Mohamed I Elsaid (Mohamed Elsaid)